Athersys, Inc. is a biotechnology company. It is engaged in the discovery and development of therapeutic product candidates. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. The MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. It is enrolling a pivotal Phase II/III clinical trial evaluating MultiStem cell therapy in COVID-19 induced and other pathogen-induced acute respiratory distress syndrome (ARDS) patients.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)